Taking everything into account, MNMD scores 2 out of 10 in our fundamental rating. MNMD was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of MNMD is average, but there are quite some concerns on its profitability. MNMD does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year MNMD has reported negative net income.
MNMD had a negative operating cash flow in the past year.
MNMD had negative earnings in each of the past 5 years.
In the past 5 years MNMD always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -70.95%, MNMD is doing worse than 71.73% of the companies in the same industry.
With a Return On Equity value of -128.72%, MNMD is not doing good in the industry: 66.49% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-70.95%
ROE	-128.72%
ROIC	N/A

ROA(3y)-48.75%

ROA(5y)-48.92%

ROE(3y)-68.39%

ROE(5y)-62.24%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MNMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MNMD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MNMD has more shares outstanding
The debt/assets ratio for MNMD has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 3.86 indicates that MNMD is not in any danger for bankruptcy at the moment.
MNMD has a better Altman-Z score (3.86) than 68.06% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that MNMD is not too dependend on debt financing.
MNMD has a Debt to Equity ratio (0.31) which is in line with its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.31
Debt/FCF	N/A
Altman-Z	3.86

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.30 indicates that MNMD has no problem at all paying its short term obligations.
MNMD has a Current ratio of 3.30. This is comparable to the rest of the industry: MNMD outperforms 54.97% of its industry peers.
A Quick Ratio of 3.30 indicates that MNMD has no problem at all paying its short term obligations.
The Quick ratio of MNMD (3.30) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	3.3
Quick Ratio	3.3

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MNMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.27%, which is quite good.

EPS 1Y (TTM)13.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-188.89%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.08% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-1.31%

EPS Next 2Y5.17%

EPS Next 3Y7%

EPS Next 5Y20.08%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MNMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNMD. No positive earnings are expected for the next year.